Tokyo, Dec. 10 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059956) titled 'Retrospective study of treatment outcomes and safety of preoperative chemotherapy for resectable esophageal cancer' on Dec. 10.
Study Type:
Observational
Primary Sponsor:
Institute - University of toyama
Condition:
Condition - Esophageal cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - Esophageal cancer is the sixth leading cause of cancer death worldwide, and the 5-year survival rate for advanced esophageal cancer is poor, at 15%. The standard neoadjuvant treatment for resectable advanced esophageal cancer has been 5-FU plus cisplatin (FP therapy). However, in 2024, it was reported that FP plus docetaxel (DCF therapy) significantly extended overall survival compared with FP therapy (4). This study aimed to evaluate the therapeutic outcomes and safety of FP therapy and DCF therapy as neoadjuvant standard treatments for resectable advanced esophageal cancer.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - resectable esophageal cancer patient
Key exclusion criteria - none
Target Size - 100
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 11 Month 13 Day
Date of IRB - 2025 Year 11 Month 26 Day
Anticipated trial start date - 2025 Year 11 Month 26 Day
Last follow-up date - 2027 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068579
Disclaimer: Curated by HT Syndication.
